Mononuclear Cells, Platelets and Zoledronic Acid for Preventing Collapse of the Femoral Head in Osteonecrosis

• Status: Unknown status
• Trial end date: 2016-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study was mainly aimed to evaluate the efficacy of local administration of enriched bone marrow mononuclear cells, platelets and zoledronic acid for the clinical prevention of collapse of the early-stage osteonecrotic femoral head.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese PLA General Hospital
• Treatments: Diphosphonates; Zoledronic Acid

Criteria

Inclusion Criteria:

• 14-55 years of age

• Either sex

• Patients with Ficat I-II ONFH confirmed by anteroposterior and lateral X-ray and CT films

• No collapse of the femoral head

• No previous ONFH-related surgery

• Tolerant to anesthesia and surgical procedures

Exclusion Criteria:

• Inability to tolerate surgical procedures

• Blood diseases

• Bleeding tendency

• Drug addictions (narcotics, anesthetics and/or alcohol)

• Inflammatory arthritis (specific or non-specific arthritis)

• Immune system disorders

• Metabolic disease (gout, rheumatism)

• Lactating or pregnant women, or women who are preparing to conceive within

1 year after initial recruitment

• Patients with psychiatric disorders who have poor compliance and cannot complete the rehabilitation therapy